XBiotech S-1 Analysis (NASDAQ: XBIT)

XBiotech Technologies Basic Info

Exchange: NASDAQ

Proposed Symbol: XBIT

Employees: 56

CEO: John Simard

Offer Amount: $80 mm

Price Range: $18-20

Expected IPO Date: 04/15/15

Description from S-1: “XBiotech is a clinical-stage biopharmaceutical company engaged in discovering and developing “True Human™” monoclonal antibodies for treating a variety of diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. While focused on bringing our lead product candidate to market, we also have developed a “True Human™” pipeline and manufacturing system.”

From the S-1


  • Lead Underwriter: WR Hambrecht

Allocation of Proceeds:

  • $30 million to complete Phase III trials for Xilonix™ in the United States and in Europe
  • $12 million on plant and equipment infrastructure to complete the manufacturing and R&D facilities under construction
  • $4 million to complete a Phase I/II study for a treatment for S. aureus infections
  • $2 million to complete a Phase II PG study
  • the remainder for working capital and general corporate purposes

Total Assets: $62.177 mm

Competitors: Xencor (XNCR), Alder Biopharma (ALDR), MannKind (MNKD)

Other Notes

  • Based in Austin, Texas
  • Founded in 2005
  • They develop antibody therapies for oncology, dermatology, diabetes, cachexia and cardiovascular disease.
  • The XBiotech founder, John Simard, also founded CTL Imunotherapies and AlleCure, both of which were merged with MannKind (MNKD) in 2001.
  • Other Recent IPOs in XBIT’s Sector have incredible aftermarket returns:
    • XNCR: 190%
    • ALDR: 194.7%
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s